Home Featured Page 166

Featured

Latest

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout...

The View from D.C.: Psychedelic Politics, Blockers and Approvals on the Horizon

Logan Davidson – American Ibogaine, State Strategy, and the Future of Psychedelic Policy

Areyto Boriken – Ethnobotanical Adventure

The Ram Dass Institute of Psychedelic Studies with The Dying Inaugural Event on Maui

Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment...

Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to...

Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million...

PT331 – Julie Zukof & Dr. Michelle Weiner – Psychedelic Women,...

Stephen Bardin to Join atai Life Sciences as CFO Designate

Small Pharma to Participate in the H.C. Wainwright 1st Annual Mental...

Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year...

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine...

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians...

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet...

1...165166167...303 Page 166 of 303

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to...

The View from D.C.: Psychedelic Politics, Blockers and Approvals on the...

Logan Davidson – American Ibogaine, State Strategy, and the Future of...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.